



# EAGEN

EUROPEAN ASSOCIATION FOR GASTROENTEROLOGY,  
ENDOSCOPY AND NUTRITION

## ***Gastrointestinal Microbiota in Health and Disease. What is the current evidence?***

### **Postgraduate Course**

Magdeburg, September 15, 2016

Course Directors: P. Malfertheiner, A. Gasbarrini, F. Megraud

8.30h	Welcome and introduction to the course	
<b>8.35h - 9.55h</b>	<b>Gastrointestinal Microbiota in Health</b> Chair: T. Matysiak, France Th. Meyer, Germany	
8.35h – 9.05h	Coevolution of gastrointestinal microbiota and the immune system - State of the art	M. Blaser, USA
9.05h – 9.20h	Gastrointestinal microbiota and the contribution to healthy aging (aging) 3 key questions with voting	M. Rajlic- Stojanovic Serbia
9.20h - 9.30h	How to modulate an ideal microbiota consortium in the gut: the role of nutrition and lifestyle 3 key questions with voting	AR. Moschen, Austria
9.30h - 9.40h	How to modulate an ideal microbiota consortium in the gut: the role of nutrition and lifestyle special comments	F. Franceschi, Italy
9.40h – 9.55h	Question & Answers	
<b>9.55h – 11.00h</b>	<b>Antibiotics and the Gut Microbiota</b> Chair: J. Regula, Poland, P. Dite, Czech Republic	
9.55h – 10.10h	selected case scenario 3 key questions with voting	A.Stallmach, Germany



# E A G E N

EUROPEAN ASSOCIATION FOR GASTROENTEROLOGY,  
ENDOSCOPY AND NUTRITION

10.10h - 10.20h	Antibiotics and the gut microbiota special comments	F. Megraud, France
10.20h - 10.40h	Pro/Cons session on diverticular disease with TV* PRO: CON:	T.Milosavljevic, Serbia L. Lundell, Sweden
10.40h – 11.00h	BREAK	
<b>11.00h – 13.00h</b>	<b>Gastrointestinal Microbiota in Disease</b> Chair: P. Malfertheiner, Germany S. Suerbaum, Germany F. Di Mario, Italy	
11.00h - 11.15h	H. pylori and other gastric microbiota in gastroduodenal pathologies	E. El-Omar, UK
11.15h - 11.25h	A case scenario patient with gastric cancer 3 key questions with voting	C. Schulz, Germany
11.25h - 11.35h	H. pylori and other gastric microbiota in gastroduodenal pathologies – special comments	L. Engstrand, Sweden
11.35h - 11.50h	Gastrointestinal microbiota in the complexity of liver disease 3 key questions with voting	A. Gasbarrini, Italy
11.50h - 12.00h	Gastrointestinal microbiota in the complexity of liver disease – special comments	K. Schütte, Germany
12.00h - 12.15h	Gastrointestinal microbiota in obesity and metabolic syndrome 3 key questions with voting	P. Portincasa, Italy
12.15h - 12.25h	Gastrointestinal microbiota in obesity and metabolic syndrome – special comments:	J. Mayerle, Germany



# EAGEN

EUROPEAN ASSOCIATION FOR GASTROENTEROLOGY,  
ENDOSCOPY AND NUTRITION

12.25h - 12.45h	<u>Moderation: J. Mayerle, Germany</u> Special session: Bariatric surgery vs. medical therapy for the metabolic syndrome - impact on gut microbiota 4 statements for interaction with audience	L. Lundell, Sweden
12.45h – 12.55h	Question & Answers	
12.55h - 14.00h	LUNCH	
<b>14.00h – 15.45h</b>	<b>5 Messages for each TOPIC</b> Chair: E. Kuipers, Netherlands, C. O'Morain, Ireland	
14.00h – 14.15h	Gut microbiota and its role in allergic diseases	A. Mueller, Switzerland
14.15h – 14.30h	Gut microbiota in IBD	S. Schreiber, Germany
14.30h – 14.45h	Gut microbiota and colon neoplasia	G. L. Hold, UK
14.45h – 15.00h	Gut microbiota: Relentless progress in diagnostics	M. Vital, Germany
15:00h – 15.15h	Gut microbiota and psychiatric diseases	T. Frodl, Germany
15.15h – 15.30h	Question & Answer Session	
15.30h – 15.45h	BREAK	
<b>15.45h – 16.30h</b>	<b>Gastrointestinal Microbiota as Therapeutic Principles</b> Chair: G. Krejs, Austria, T. Milosavljevic, Serbia	
15.45h – 16.05h	Probiotic bacterial species/strains: where is the evidence for efficacy – new trials	P. Marteau, France
16.05h – 16.25h	Probiotic fungal therapy in clinical practice with presentation of algorithms	H. Szajewska, Poland
16.25h – 16.30h	Question & Answer Session	



# EAGEN

EUROPEAN ASSOCIATION FOR GASTROENTEROLOGY,  
ENDOSCOPY AND NUTRITION

**16.30h – 17.00h Meet the Professor in Round Table (both groups in main room)**

1) Fecal microbiota transplantation: established indications and future views T. Rokkas &

How to do? F. Scaldaferri & A. Link

2) Management of antibiotic resistance and the role of probiotics: H. pylori, MRSA, VRSE F. Megraud & C. Schulz

++ END OF POSTGRADUATE COURSE ++